Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer

Data presented by Johnson & Johnson at the 2026 European Society for Radiotherapy and Oncology (ESTRO) Annual Meeting

PARIS and CAMBRIDGE, Mass., May 17, 2026 (GLOBE NEWSWIRE) --  NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of Part 1 data from the CONVERGE study, a Johnson & Johnson-sponsored randomized Phase 2 clinical trial evaluating potential first-in-class Nanoradioenhancer JNJ-1900 (NBTXR3) for patients with stage 3 inoperable non-small cell lung cancer (“NSCLC”), at the 2026 European Society for Radiotherapy and Oncology Annual Meeting (ESTRO 2026).

PRESENTATION #116: Radiographic Response in Patients with Stage III Unresectable Non-Small Cell Lung Cancer Treated with an Intratumoral Radioenhancer (JNJ-90301900)

Jeffrey Bradley,¹ Benjamin T. Cooper,² Sushma Patel,³ David DiBardino,⁴ Michael Pritchett,⁵ Kevin C. Ma,⁴   Isaac Laniado,⁶ Melina E. Marmarelis,⁷ Matthew Scarlotta,⁸ Joshua K. Sabari,⁹ Yi -Wen Ma,¹⁰ Tori Stromp,¹⁰ Yina Kuang,¹⁰ Balaji Laxmanan,¹⁰ Kiran Devisetty,¹⁰ Steven Feigenberg¹

Study Conclusions

• Early results suggest that intratumoral/intranodal injection of JNJ-1900 (NBTXR3) is feasible and can be performed safely in patients with stage III unresectable NSCLC
• Initial efficacy responses observed in 7 patients following the full treatment regimen of concurrent chemoradiotherapy, JNJ-1900 (NBTXR3), and consolidation with durvalumab are promising:
  • Overall response rate (“ORR”) = 85.7% (6/7 patients)
  • Complete response rate (“CRR”) = 57.1% (4/7 patients)
    • With the current standard of care, concurrent chemoradiation therapy (cCRT) ± durvalumab, depth of response remains limited in Stage 3 Inoperable NSCLC with very low rates of complete response (<5%) * 
  • Disease control rate (“DCR”) = 100.0% (7/7 patients)
• Absence of progressive disease and deepening response over time suggests potential for long-term durability

¹Radiation Oncology, University of Pennsylvania, Philadelphia, USA; ²Radiation Oncology, NYU Langone Health, New York, USA; ³Radiation Oncology, FirstHealth of the Carolinas, Pinehurst, USA; ⁴University of Pennsylvania, Philadelphia, USA; ⁵Interventional Pulmonology, FirstHealth of the Carolinas, Pinehurst, USA; ⁶Interventional Pulmonology, NYU Langone Health, New York, USA; ⁷Medical Oncology, University of Pennsylvania, Philadelphia, USA; ⁸Medical Oncology, FirstHealth of the Carolinas, Pinehurst, USA; ⁹Medical Oncology, NYU Langone Health, New York, USA; ¹⁰Johnson & Johnson, New Brunswick, NJ, USA

Schreibe Deinen Kommentar